Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

Summary

The purpose of this study is to evaluate the antitumor activity of sunitinib in patients with advanced/inoperable fibrolamellar hepatocellular carcinoma. Rationale: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

Timeline

Start

2009-10

Primary completion

2011-05

Completion

2012-05

Outcome

Outcome not reported

Stopped: “lack of inclusion”

Drugs

Indications